BioSpace News Archive

PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2024.

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced that its founder, president and chief executive officer, Derek Maetzold, has been named by Ernst & Young LLP as an Entrepreneur Of The Year® 2024 Gulf South Award winner.

Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status.

Theralase® Technologies Inc. is providing a reminder notice for its Annual General and Special Meeting for shareholders of Theralase® that is scheduled for Wednesday, June 19th at 4:30 pm ET at its corporate head office; specifically, 41 Hollinger Road, Toronto, Ontario, M4B 3G4.

Aptose Biosciences Inc. announced a clinical poster presentation and a preclinical e-poster at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain.

Wugen, Inc. announces positive Phase 2 results for the company’s investigational anti-CD7 CAR-T therapy, WU-CART-007, in patients with relapsed/refractory t-cell acute lymphoblastic leukemia/lymphoma.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, announced that it entered into separate, privately negotiated exchange agreements with certain holders of its 2.75% Convertible Senior Notes due 2027.

Cogent Biosciences, Inc. announced additional data from Part 1 of its ongoing SUMMIT clinical trial evaluating the selective KIT D816V inhibitor, bezuclastinib, in patients with nonadvanced systemic mastocytosis.

Mereo BioPharma Group plc, a clinical-stage biopharmaceutical company focused on rare diseases, announced the pricing of an underwritten offering of 12,531,300 of its American Depositary Shares.

Lexicon Pharmaceuticals, Inc. announced that three poster presentations will be delivered during the 84th Scientific Sessions of the American Diabetes Association being held June 21 - 24, 2024 at the Orange County Convention Center in Orlando, Florida.